FTC sues Endo Pharmaceuticals for paying off generic drugmakers – and delaying market entry
The Federal Trade Commission has sued Endo Pharmaceuticals and several other drugmakers, saying they've entered "pay-for-delay" deals that postpone generic versions of its drugs to hit the market.